LSLiudmila Shats

Liudmila Shats

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liudmila Shats has a total of 104 co-authors. Here are the top co-authors by number of shared publications:

  • Margarita B. Belogurova

    Almazov National Medical Research Centre, Ministry of Health of Russia; Saint Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological) named after N.P. Napalkov

    3 shared publications
  • A. A. Ivchenko

    Stavropol Regional Children’s Clinical Hospital

    1 shared publication
  • A. E. Rudneva

    Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology

    1 shared publication
  • A. P. Ektova

    Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology

    1 shared publication
  • A. S. Seregin

    Samara State Medical University, Ministry of Health of Russia; Samara Regional Clinical Hospital named after V.D. Seredavin

    1 shared publication
  • A. V. Nechesnuk

    Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology

    1 shared publication

Latest Publications

  • Case report of pediatric arteriovenous malformation of inferior turbinate

    by S. Alekseenko, Saint Petersburg Raukhfus Children'S Clinical Center Of High Medical Technologies, E. K. Tikhomirova, Ya. E. Kuznetsova, L. I. Shats

    Congenital arteriovenous malformations (AVMs) of the head and neck are not common in clinical practice. They may have various manifestations — from minor aesthetic changes to severe hemodynamic disorders. Diagnosis and treatment of AVM is a difficult task. Atypical structure of the vascular wall can provoke intense intraoperative bleeding, and incomplete removal of the neoplasm leads to a high risk of tumor recurrence. The clinical observation under review presents a rare case of AVM of the inferior nasal basin in a 5-year-old child who initially presented to the hospital with nasal bleeding. Surgical method is the only way of radical treatment of AVM. We chose the safest minimally invasive technique — endonasal endoscopic approach that allowed total removal of the AVM without hemorrhagic complications.

  • Open Access

    Possibilities of medical treatment of infantile hemangiomas in Russia

    by N. P. Kotlukova, T. S. Belysheva, L. I. Shats, V. A. Fochenkova, E. D. Chavpetsova, M. B. Belogurova, Yu. K. Toshina, Yu. V. Dinikina, I. N. Nurmeev, A. S. Seregin, et al.

    Introduction. Infantile hemangiomas (IH) are the most common benign vascular tumor of children of the first year and are an interdisciplinary problem of neonatologists, pediatricians, pediatric cardiologists, oncologists, pediatric surgeons, dermatologists. Depending on the age of child, phase of pathological process, size, and localization of the IH, the management tactics of such children can be conservative (pharmaceuticals therapy) or invasive (laser therapy, surgical methods). Laser therapy with a pulsed dye laser has proven itself well to correct and minimize residual phenomena because of spontaneous involution and after the completion of pharmaceuticals treatment.The purpose of the study is to analyze the experience of using Hemangiol® (oral solution) for the treatment of children with IH, obtained in 10 medical hospitals in 6 cities of Russia.Materials and methods. Treatment with Hemangiol® was carried out in 6 cities of Russia on the basis of 10 medical hospitals (Children’s CityClinical Hospital named after Z.A. Bashlyaeva of Moscow City Health Department, Research Institute of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia (Moscow), Russian Children’s Clinical Hospital of the N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia (Moscow), Children’s City Clinical Hospital named after N.F. Filatov of Moscow City Health Department, Saint Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological) (S.-Petersburg), Almazov National Medical Research Centre, Ministry of Health of Russia (S.-Petersburg), Rostov Regional Clinical Hospital (Rostov-on-Don), Stavropol Regional Children’s Clinical Hospital (Stavropol), Samara Regional Clinical Hospital named after V.D. Seredavin, Children’s Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan (Kazan) in the Departments of Pediatric Cardiology, Surgery, Oncology, Pediatrics from January 2020 to December 2021. Therapy with Hemangiol® was received by 49 children with IH for at least 3 months. Before the start of treatment, the patients’ heart rate and blood pressure were measured, general and biochemical blood tests were performed, electrocardiography and ultrasound IH were performed. According to the indications, ultrasound of the liver and thyroid gland was performed to determine the parameters of the thyroid status. Before the start of therapy and during dynamic observation, photo documentation was performed against the background of treatment. In the absence of contraindications to treatment, Hemangiol® was prescribed. During a six-month course of treatment with Hemangiol®, effectiveness was evaluated based on the results of a clinical examination and based on photographs. The appearance of possible adverse reactions was monitored.Results. In 33 (67.3 %) children with IH, therapy with Hemangiol® was completed within 6 months. The effect of treatment in the form of a pronounced regression of vascular tumor was achieved in 25 (75.8 %) of 33 patients. In 16 (32.7 %) of 49 children, treatment with Hemangiol® was continued for more than 6 months. The first symptoms of improvement were observed from the second to 10 days after the start of Hemangiol® therapy in 45 patients, which was (91.8 %). Rebound syndrome (recurrence of IH) was detected in 2 (6.0 %) of 33 children who completed therapy. Transit adverse reactions (decreased heart rate, increased excitability, lethargy) on therapy of Hemangiol® were observed in 8 (16.3 %) children. The duration of therapy with Hemangiol® depended on the prevalence, the depth of the IH lesion, as well as on the presence of prematurity in a child with IH (r = 0.533, p < 0.05). Successful laser treatment with a pulsed laser on a dye after the completion of systemic Hemangiol® therapy, were on 5 children of Research Institute of Pediatric Oncology and Hematology at N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia.Conclusion. The results of the using of Hemangiol® as a modern means of systemic pharmacotherapy of IH therapy in 10 medical hospitals in 6 cities of Russia have demonstrated its high efficiency and safety.


  • Open Access

    Nephrogenic rests and nephroblastomatosis: literature review and clinical reports

    by L. I. Shats, B. V. Kondratiev, M. B. Belogurova

    Nephrogenic rests and nephroblastomatosis describe persistence of embryonic renal parenchyma (metanephric blastema) beyond 36 weeks of gestation, when nephrogenesis is normally complete. This persistent metanephric blastema may transform into the Wilms tumor, and are detected in 30–40 % of unilateral nephroblstoma and nearly 100 % in bilateral cases. The risk of Wilms tumour is increased in any type of nephrogenic rests/nephroblastomatosis but it is higher in infants and in patients with intralobar nephrogenic rests. We cite below several studies described different types of nephrogenic rests, their connection with nephroblastoma development and the details of diagnostic. We refer to clinical examples, in that regard. Two cases are presented: bilateral diffuse hyperplastic perilobar nephroblastomatosis in one child and an infant with combination of perilobar nephrogenic rests in one kidney and Wilms tumour in the other kidney.


  • Open Access

    Subsequent gliomas in survivors of paediatric neoplasms

    by L. I. Shats, M. B. Belogurova, S. S. Ozerov, A. P. Ektova, A. V. Nechesnuk, M. V. Rizhova, O. V. Vizhlukova, I. V. Doronina, H. V. Tsirenova, E. V. Grishina, et al.

    Multimodal therapy has improved survival for most childhood tumours. The development of neoplasms subsequent to therapeutic cranial irradiation is a rare but serious and potentially fatal complication. The analysis included 16 patients (pts.) with subsequent glioblastoma (SG) from several institutions in Russia who underwent cranial or neck irradiation (1 case) to treat their primary disease (acute lymphoblastic leukaemia – 12 pts., medulloblastoma – 2 pts., choroid plexus papilloma – 1 pts., lymphoma – 1 pts.). All gliomas arose within the previous radiation fields and satisfied the widely used criteria for the definition of radiation induced neoplasms. The median RT dose administered was 18 Gy with the dosage ranges being 12–55 Gy. TBI was used in one patient with Ph-positive ALL during bone marrow transplantation. Median latency period was 6 years until diagnosis of SG. The majority of SG (14 of 16) occurred during the initial 9 years of follow-up. Patients underwent surgery resection followed by standard fractionated local radiation and chemotherapy. A Kaplan–Meier analysis was used to illustrate the overall survival (OS) curves. OS rate was 34.4 ± 12.3% and 13,6 ± 9.0% at 1 and 2 years respectively with median 11 months. In case that paediatric neoplasms are treated by standard fractionated radiation or TBI is used, radiation-induced gliomas should be considered as possible long-term side effect. And the patients should be followed for a long term, even long after the period of risk for relapse of the primary cancer has passed.


  • Open Access

    Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease

    by On Behalf Of The Members Of The Siope Dipg Network, Sophie E. M. Veldhuijzen van Zanten, Joshua Baugh, Brooklyn Chaney, Dennis De Jongh, Esther Sanchez Aliaga, Frederik Barkhof, Johan Noltes, Ruben De Wolf, Jet Van Dijk, et al.

    Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly childhood malignancy. After 40 years of mostly single-center, often non-randomized trials with variable patient inclusions, there has been no improvement in survival. It is therefore time for international collaboration in DIPG research, to provide new hope for children, parents and medical professionals fighting DIPG. In a first step towards collaboration, in 2011, a network of biologists and clinicians working in the field of DIPG was established within the European Society for Paediatric Oncology (SIOPE) Brain Tumour Group: the SIOPE DIPG Network. By bringing together biomedical professionals and parents as patient representatives, several collaborative DIPG-related projects have been realized. With help from experts in the fields of information technology, and legal advisors, an international, web-based comprehensive database was developed, The SIOPE DIPG Registry and Imaging Repository, to centrally collect data of DIPG patients. As for April 2016, clinical data as well as MR-scans of 694 patients have been entered into the SIOPE DIPG Registry/Imaging Repository. The median progression free survival is 6.0 months (95% Confidence Interval (CI) 5.6–6.4 months) and the median overall survival is 11.0 months (95% CI 10.5–11.5 months). At two and five years post-diagnosis, 10 and 2% of patients are alive, respectively. The establishment of the SIOPE DIPG Network and SIOPE DIPG Registry means a paradigm shift towards collaborative research into DIPG. This is seen as an essential first step towards understanding the disease, improving care and (ultimately) cure for children with DIPG.